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SUMMARY
Interleukin-1b (IL-1b) is a potent inflammatory cyto-
kine that is usually cleaved and activated by inflam-
masome-associated caspase-1. To determine
whether IL-1b activation is regulated by inhibitor of
apoptosis (IAP) proteins, we treated macrophages
with an IAP-antagonist ‘‘Smac mimetic’’ compound
or genetically deleted the genes that encode the three
IAP family members cIAP1, cIAP2, and XIAP. After
Toll-like receptor priming, IAP inhibition triggered
cleavage of IL-1b that was mediated not only by the
NLRP3-caspase-1 inflammasome, but also by cas-
pase-8 in a caspase-1-independent manner. In the
absence of IAPs, rapid and full generation of active
IL-1b by the NLRP3-caspase-1 inflammasome, or
by caspase-8, required the kinase RIP3 and reactive
oxygen species production. These results demon-
strate that activation of the cell death-inducing ripop-
tosome platform and RIP3 can generate bioactive
IL-1b and implicate them as additional targets for
the treatment of pathological IL-1-driven inflamma-
tory responses.
INTRODUCTION
Release of the proinflammatory interleukin-1 (IL-1) family
members IL-1a and IL-1b and their engagement of the IL-1
receptor modulates sterile inflammatory responses and acti-
vates host immune defenses against a range of human patho-
gens (Menu and Vince, 2011). The cleavage-induced activation
and secretion of IL-1b is signaled by several cytosolic NLRs
(NOD-like receptors) and the HIN-200 family member AIM2
(Schroder and Tschopp, 2010). These proteins respond to host
DAMPs (damage-associated molecular patterns) and microbial
PAMPs (pathogen-associated molecular patterns) to form large
multimeric protein complexes known as inflammasomes. Inflam-
masomes recruit and activate caspase-1 either directly or indi-
rectly via the adaptor protein ASC, leading to caspase-1
cleavage and activation of precursor IL-1b.
The most-studied inflammasome to date is NLRP3 (also
known as NALP3). Mutations in NLRP3 associated with heritable
cryanopanopathies cause increased inflammasome activation
and these diseases are successfully treated by anti-IL-1 therapy
(Menu and Vince, 2011). NLRP3 is activated by a variety of
PAMPs such as bacterial pore-forming toxins and viral DNA
(Hoffman and Brydges, 2011). More recently, NLRP3 inflamma-
some sensing of sterile DAMPs or environmental irritants that
contribute to diseases such as atherosclerosis (cholesterol
crystals), Alzheimer’s (b-amyloid), type II diabetes (islet amyloid
polypeptide, ceramide, saturated fatty acids), pulmonary fibrotic
disorders (asbestos, silica dioxide), and gout (monosodium ur-
ate) has been reported (Rock et al., 2010). The diversity and
number of NLRP3 stimuli suggest that NLRP3 is an important
sensor for specific metabolic disturbances. Although the precise
mechanism governing NLRP3 activation remains unresolved,
current models propose a role for mitochondrial reactive oxygen
species (ROS) generation, potassium efflux, and phagolysoso-
mal damage (Jin and Flavell, 2010).
Until recently, IAP proteins were primarily known for inhibiting
apoptotic caspase activity. In mammals, XIAP (X chromosome-
linked IAP) binds and inhibits caspase-9, caspase-3, and
caspase-7 through evolutionary conserved baculoviral IAP
repeat (BIR) motifs and a RING finger E3 ligase domain (Gyrd-
Hansen andMeier, 2010). Although they contain a similar domain
structure to XIAP, the related IAP proteins cellular IAP-1 (cIAP1)
and cellular IAP-2 (cIAP2) do not directly inhibit caspase proteo-
lytic activity (Eckelman and Salvesen, 2006).
Because IAP expression can prevent cell death and may
promote cancer cell survival, IAP antagonist compounds, known
as Smac mimetics, have been developed. Like mature mamma-
lian Smac, Smac mimetics bind to the BIR2 and BIR3 grooves of
IAP proteins, resulting in the loss of XIAP-mediated caspase inhi-
bition (Dynek and Vucic, 2010). An unexpected finding was that
Smac mimetic targeting of cIAP1 induces cIAP1 dimerization
and activation of its E3 ligase activity, resulting in ubiquitylation
and proteasomal degradation of itself and cIAP2 (Darding
et al., 2011; Feltham et al., 2011; Varfolomeev et al., 2007; Vince
et al., 2007).
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Our knowledge of IAP protein function has expanded rapidly
with the development and use of Smac mimetics, and IAPs are
now recognized as key regulators of mammalian immunity
through their control of TNF receptor and pattern-recognition
receptor (PRR) family signaling pathways. IAP inhibition can
sensitize cells to TNFR1-, TLR3-, or TLR4-induced apoptosis
or RIP3-dependent necroptosis by preventing cIAP1- and
cIAP2-mediated ubiquitylation of core signaling components
such as RIP1 kinase (Feoktistova et al., 2011; Gyrd-Hansen
and Meier, 2010; He et al., 2011; Weber et al., 2010). IAPs also
promote TLR2 and TLR4 cytokine production by inducing the
degradation of the adaptor protein TRAF3 (Tseng et al., 2010)
and control signaling from the viral RNA receptor RIG-I by cata-
lyzing nondegradative ubiquitylation of TRAF3 and TRAF6 (Mao
et al., 2010). Ubiquitylation of RIP2 by cIAP1 and cIAP2 is also
required for cytokine production by the NLR family members
NOD1 and NOD2, which detect bacterial peptidoglycans (Ber-
trand et al., 2009).
These reports and others demonstrate that IAP proteins
largely promote innate immune activation by facilitating PRR-
dependent transcriptional responses. Here we reveal an unex-
pected role for IAPs in negatively regulating inflammatory
responses by limiting RIP3 kinase-dependent activation of
NLRP3-caspase-1 and -caspase-8 pathways that can indepen-
dently promote IL-1b precursor maturation and secretion.
RESULTS
The Smac Mimetic Compound A Induces Activation
and Secretion of Caspase-1 and IL-1
To determine whether IAPs can modulate IL-1 secretion, we
primed bone marrow-derived dendritic cells (BMDCs) with LPS
to induce intracellular IL-1b precursor expression and then
treated them with a bivalent Smac mimetic, compound A (Vince
et al., 2007), and examined IL-1a and IL-1b release into the
supernatant. Cells primed with LPS before compound A treat-
ment released substantial amounts of both IL-1a and IL-1b
within 6 hr, as detected by ELISA (Figures 1A and 1B).
To determine whether the IL-1b secreted in response to Smac
mimetic was the mature, biologically active form and whether its
release correlated with caspase-1 activation, we also analyzed
cell supernatants and lysates by immunoblot (Figure 1C).
LPS-primed cells treated with the NLRP3 inflammasome
agonist alum promoted the secretion of processed caspase-1
and the biologically active 17 kDa IL-1b cleavage fragment
(Eisenbarth et al., 2008). Similarly, compound A treatment re-
sulted in the canonical processing and secretion of IL-1b and
caspase-1 and was effective at doses as low as 100 nM (Fig-
ure 1C and Figure S1A available online). Compound A cotreat-
ment with the NLRP3 activators alum or R837 also increased
IL-1a, IL-1b, and caspase-1 activation and secretion from
BMDMs compared to treatment with either agent alone (Figures
1D, 1E, S1B, and S1C). Notably, compound A-treated BMDCs
that were primed with other TLR or TNF receptor ligands also
caused substantial caspase-1 and IL-1b activation and secre-
tion (Figures 1F and S1D). Despite the fact that compound A
is a potent activator of noncanonical NF-kB (Vince et al.,
2007), by itself it was unable to markedly induce precursor
IL-1b production (Figure 1C).
The mechanism of IL-1a and IL-1b release from the cell is still
unclear but may involve cell death or pore formation in the
plasma membrane (Eder, 2009). To determine whether Smac
mimetic increased BMDC or BMDM death or pore formation,
we stained cells with propidium iodide (PI) (Figure 1G) or PI
and annexin V (Figure S1E) after 8 hr of treatment, 2 hr after all
IL-1 assays were performed. At this time point, LPS-primed
and compound-treated cells showed no significant difference
in PI or annexin V staining compared to untreated cells, whereas
staurosporine, cycloheximide, and ATP all induced significant
amounts of PI and annexin V uptake (Figures 1G and S1E). These
data indicate that Smac mimetic-induced caspase-1 and IL-1
activation takes place before cell death occurs.
Combined Genetic Deletion of XIAP, cIAP1, and cIAP2
Recapitulates Smac Mimetic-Induced Caspase-1
and IL-1b Activation
Compound A promotes the rapid degradation of cIAP1 and
cIAP2 and also antagonizes XIAP function. To investigate which
IAP protein was critical in regulating IL-1b activation, we took
advantage of XIAP-deficient mice and conditionally gene-tar-
geted cIAP1 (encoded by Birc2) and cIAP2 (encoded by Birc3)
mice (Gardam et al., 2011). Single, double, and triple IAP-defi-
cient BMDMs were treated with LPS alone, or LPS followed by
NLRP3 stimuli, and cell supernatants and lysates analyzed by
immunoblot (Figures 2A and 2B). All IAP gene-targeted cells
responded in a similar way to wild-type (WT) cells by only
producing IL-1b precursor in response to LPS priming (Fig-
ure 2B). WT, single, and double IAP-deficient macrophages
secreted substantial amounts of active caspase-1 and IL-1b
only when treated with the NLRP3 agonists alum (Figures 2A
and 2B), nigericin, or ATP (Figure S2A). In contrast, but recapit-
ulating Smac mimetic treatment of WT macrophages, triple
IAP-deficient BMDMs activated and secreted large amounts of
caspase-1 and IL-1b when primed with LPS alone (Figure 2A).
Consistent with the requirement for the inhibition of all three
IAPs for maximal IL-1b activation, LPS-primed Xiap/ or
Xiap/Birc3/ BMDMs secreted large amounts of IL-1b only
when treated with compound A to remove the remaining IAPs
(Figure S2B). Although ELISA detection revealed that LPS
priming induced some IL-1b secretion in Xiap/Birc3/
BMDMs, this was substantially lower than when all three IAPs
were deleted or inhibited (Figures 2A and S2B). LPS treatment
also induced caspase-3 and PARP cleavage in triple IAP-defi-
cient and Xiap/Birc3/ cells, and to a lesser extent Xiap/
BMDMs (Figure 2B). However, PI and Annexin V staining demon-
strated that cell death in response to IAP inhibition occurs after
IL-1b activation (Figures 1G and S1E and data not shown).
Both transforming growth factor-b-activated kinase 1 (TAK1)
and TRAF2 have been implicated in the signaling pathways
affected by Smac mimetic treatment (Darding et al., 2011;
Vanlangenakker et al., 2011). TRAF2-targeted cells respond in
a similar way to Smac mimetic-treated or IAP-deficient cells,
with spontaneous noncanonical NF-kB activation and sensitiza-
tion to death receptor killing (Grech et al., 2004; Vince et al.,
2009). We therefore tested whether TRAF2- or TAK1 (encoded
byMap3k7)-deficient BMDMs activated IL-1b similar to IAP-defi-
cient or Smac mimetic-treated cells. However, unlike IAP-defi-
cient cells, LysM-cre Traf2/ and LysM-creMap3k7/BMDMs
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did not markedly activate caspase-1 or process IL-1b in
response to LPS treatment alone (Figures 2C and 2D). Further-
more, when treated with LPS plus compound A, alum, or niger-
icin, these cells processed and secreted IL-1b similar toWT cells
(Figures 2C, 2D, S2C, and S2D). An occasional small increase in
caspase-1 activation in TRAF2- or TAK1-deficient macrophages
treated with compound A alone was not significant and did result
in increased IL-1b secretion (Figures 2C, S2C, and S2D).
Inhibition of IAP Proteins Results in NLRP3-Caspase-1
Inflammasome-Dependent and -Independent IL-1
Activation
Our results suggested that the three IAPs act together to
suppress caspase-1 activation. We therefore examined which
inflammasome might be activated by loss of IAP function.
Deletion of NLRP3 reduced compound A-stimulated IL-1a and
IL-1b secretion to a similar extent as observed in Pycard/
(also known as Asc) or Casp1/ BMDCs (Figures 3A, 3B, and
S3B) and BMDMs (Figures 3C and S3A). Consistent with
compound A causing activation of NLRP3, caspase-1 process-
ing and its secretion was abolished in Nlrp3/ and Pycard/
BMDMs but unaffected in NLRC4 inflammasome-deficient
BMDMs (Figures 3B, 3C, S3A, and S3C).
The failure of caspase-1 to activate in Nlrp3/, Pycard/, or
Casp1/ (which also lack caspase-11 [Kayagaki et al., 2011])
cells did not completely prevent compound A-induced secretion
of IL-1b (Figures 3A–3C and S3A) or IL-1a (Figure S3B). It has
been described that TWEAK ligand can mimic compound A by
reducing the amounts of cIAP1, cIAP2, and TRAF2 (Varfolomeev
et al., 2007; Vince et al., 2008). However, TWEAK treatment did
Figure 1. The Smac Mimetic Compound A Induces Caspase-1 and IL-1 Activation and Secretion from Macrophages and Dendritic Cells
(A and B) BMDCSwere primed with LPS as indicated and treated with 200 nM of Cp. A for the times shown. IL-1a (A) and IL-b (B) release into the supernatant was
measured by ELISA. The mean (bars) and measurements of three replicate experiments is shown.
(C) BMDMswere primed with LPS and treated with varying doses of Cp. A (100–500 nM) or alum (250 mg/ml) for 6 hr. Cell supernatants and lysates were analyzed
by immunoblot.
(D and E) BMDMs were primed with LPS as indicated and then treated with alum (250 mg/ml) or R837 (10 mg/ml) ± Cp. A (200 nM) for 6 hr. IL-1a (D) and IL-b (E)
release into the supernatant was measured by ELISA. The mean (bars) and measurements of three replicate experiments is shown.
(F) BMDCs were primed for 3 hr with ligands for TLR2 (P3Cys (tripalmitoyl-S-glyceryl-Cys-Ser-4(Lys), 2 mg/ml), TLR9 (CpG (CpG-containing DNA), 2 mg/ml), TLR3
(poly(I:C) [polyinosinic:polycytidylic acid], 2.5 mg/ml), or TNFR1 (TNF, 50 ng/ml). Cells were then stimulated for 6 hr with Cp. A (200 nM) and IL-1b release was
quantified by ELISA. The mean (bars) and measurements of three replicate experiments is shown.
(G) BMDMs or BMDCs were primed with LPS and then treated with 200 nM Cp. A or 10 mg/ml R837 for 8 hr. Cell viability was quantified by propidium iodide (PI)
staining and flow cytometry. Error bars represent the SD of cells derived from three mice.
The results from all experiments were verified on two to three separate occasions. See also Figure S1.
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not activate caspase-1 or IL-1b substantially (Figure S3A). This
further supports the idea that full activation of caspase-1 and
IL-1b requires inhibition of XIAP as well as cIAP1 and cIAP2.
Collectively, these data show that Smac mimetics must target
XIAP, cIAP1, and cIAP2 for maximal activation of NLRP3-cas-
pase-1. However, the absence of NLRP3, ASC (encoded by
Pycard), or caspase-1 fails to completely prevent Smac
mimetic-induced IL-1b maturation, suggesting that IAP proteins
also regulate an alternate IL-1b activating pathway that is inflam-
masome independent.
RIP3 Is Required for Efficient Smac Mimetic-Induced
IL-1 Activity
We considered whether RIP1 or RIP3 played a role in Smac
mimetic-induced IL-1 activation because IAP depletion can
promote the formation of RIP1 and RIP3 signaling complexes
(He et al., 2009). The deletion of RIP3 decreased Smac
mimetic-induced activation and secretion of caspase-1 and
IL-1 in BMDCs and BMDMs after LPS-TLR4 (Figures 3A, 3D,
S3B, and S3D), Pam3Cys-TLR2, or CpG-TLR9 priming (Fig-
ure 3E). Because Smac mimetic-induced IL-1 secretion was
lower inRipk3/BMDCswhen compared in parallel toNlrp3/,
Pycard/, andCasp1/BMDCs (Figures 3A, 3E, and S3B), this
suggests that RIP3 is required for optimal NLRP3-caspase-1 in-
flammasome-dependent and -independent IL-1 activation.
Experiments with increased cell numbers revealed that, although
markedly reduced, some processing of caspase-1 and IL-1b
could still occur in RIP3-deficient BMDMs (Figures S3D and
S4G). Nevertheless, these results indicate that IAPs suppress
RIP3 signaling and that RIP3 is a regulator of the NLRP3
Figure 2. Combined Genetic Deletion of XIAP, cIAP1, and cIAP2 Recapitulates Smac Mimetic-Induced Caspase-1 and IL-1b Activation
(A and B) BMDMs of the indicated genotype were primed with LPS for 3 hr as indicated and then stimulated with alum (200 mg/ml) for a further 5 hr. Cell
supernatants (A) or lysates (B) were analyzed by immunoblot.
(C and D) BMDMs of the indicated genotype were primed with LPS for 3 hr as indicated and then stimulated for 6 hr with Cp. A (200 nM) or alum (250 mg/ml) or for
1 hr with nigericin (4 mM). Cell supernatants (C) and lysates (D) were analyzed by immunoblot.
The results represent data obtained from two to six mice of each genotype. See also Figure S2.
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inflammasome and IL-1 activation. In contrast, loss of RIP3 had
no impact on alum-, R837-, ATP-, or nigericin-induced NLRP3
activity (Figure S3D and not data not shown), demonstrating
that RIP3 is not required for optimal NLRP3 activation by other
stimuli.
Because RIP3 activation usually requires RIP1 kinase function
(Cho et al., 2009; He et al., 2009; Zhang et al., 2009), we tested
whether the RIP1 kinase inhibitor Necrostatin-1 (Degterev
et al., 2008) affected Smac mimetic-induced IL-1b activation.
However, treatment of LPS-primed BMDMs with Necrostatin-1
did not alter compound A-induced IL-1b secretion (Figure 4A).
Similarly, although lysosome function and protease release or
activation has been implicated in NLRP3-dependent IL-1b acti-
vation (Hornung and Latz, 2010), inhibition of lysosome function,
cathepsins, and calpains with Bafilomycin A1, NH4Cl, CA-074-
Me, or E64d, respectively, did not alter Smac mimetic-induced
IL-1b maturation in LPS-primed WT, Nlrp3/, or Pycard/
BMDMs (Figures 4A and 4B).
RIP3-Dependent Reactive Oxygen Species Production
Is Required for Efficient Smac Mimetic-Induced IL-1b
Activation
RIP3 signaling can promote mitochondrial ROS production (Cho
et al., 2009; Vanlangenakker et al., 2011; Zhang et al., 2009),
and it has also been proposed that mitochondrial damage and
ROS generation can facilitate NLRP3-dependent IL-1b activa-
tion (Nakahira et al., 2011; Zhou et al., 2011). However, antioxi-
dants commonly used to inhibit ROS accumulation can impair
LPS induction of IL-1b precursor and NLRP3 (Bauernfeind
et al., 2011; van de Veerdonk et al., 2010) and is consistent
with a role for ROS in LPS transcriptional responses (Figures
S4A–S4D; Gloire et al., 2006).
To circumvent the effects antioxidant treatment may have on
LPS priming, we treated cells with antioxidants after LPS
priming.We observed that four different antioxidants added after
LPS priming markedly inhibited the activation of caspase-1 and
IL-1b in response to compound A (Figure 4C). Antioxidant
Figure 3. IAP Inhibition Activates IL-1 by NLRP3-Caspase-1 Inflammasome-Dependent and -Independent Mechanisms that Both Require
RIP3
(A and B) BMDCs of the indicated genotype were primed with LPS and then stimulated for a further 6 hr with the indicated doses of Cp. A. IL-1b levels in the
supernatants were detected by ELISA (A) and cell supernatants and lysates also analyzed by immunoblot (B). The mean (bars) and measurements of three
replicate experiments is shown (A).
(C) BMDMs of the indicated genotype were treated with Cp. A (200 nM) or alum (250 mg/ml) for 6 hr after LPS priming. Cell supernatants and lysateswere analyzed
by immunoblot.
(D) WT or Ripk3/ BMDCs were primed with LPS and then stimulated with the indicated doses of Cp. A for a further 6 hr. Cell supernatants and lysates were
analyzed by immunoblot.
(E) BMDCs of the indicated genotype were primed with Pam3Cys (2 mg/ml) or CpG (2 mg/ml) for 3 hr and then stimulated with 200 nM Cp. A for a further 6 hr. Cell
supernatants and lysates were analyzed by immunoblot.
All data were confirmed on two to four separate occasions. See also Figure S3.
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treatment also inhibited compound A-induced NLRP3-caspase-
1-independent secretion of IL-1b (Figure 4D). Propidium iodide
staining and LDH release assays indicated that compound A
and the antioxidant N-acetyl cysteine (NAC) were no more toxic
than other NLRP3 stimuli such as alum, yet at the same timeNAC
prevented LPS-primed and compound A-treated BMDMs from
secreting IL-1b (Figures S4E–S4G).
To determine whether RIP3 activation might induce ROS after
IAP inhibition, we compared ROS production in WT and RIP3-
deficient BMDMs. Whereas WT macrophages showed a robust
increase in ROS amounts after LPS priming and compound A
treatment, ROS generation in Ripk3/ BMDMs was impaired
(Figure 4E). In contrast, LPS or compound A stimulation
alone induced less ROS, which was similar between WT and
Ripk3 / BMDMs (Figure 4F). Consistent with NAC inhibition
of ROS, and ROS being an effecter of RIP3-dependent killing,
Ripk3/ BMDMs, or WT BMDMs treated with NAC, were
partially protected from cell death induced by prolonged (19 hr)
treatment with LPS and compound A (Figure S4H).
Compound A treatment has been shown to induce TNF
production in a subset of tumor cell lines (Vince et al., 2007).
However, TNF-TNFR1 signaling was not involved in compound
A-induced IL-1b maturation because Tnfrsf1a/ BMDMs
secreted similar amounts of active caspase-1 and IL-1b when
compared to WT BMDMs (Figure 4G). To further distinguish
between compound A-induced NLRP3-dependent and -inde-
pendent IL-1b activation, we treated cells with glyburide, an
inhibitor of NLRP3 activity (Lamkanfi et al., 2009). Glyburide
prevented caspase-1 activity in both WT and Tnfrsf1a/macro-
phages primed with LPS and treated with compound A but,
unlike alum treatment, glyburide did not completely prevent
compound A-induced IL-1b processing and secretion in either
WT, TNFR1-, NLRP3-, or ASC-deficient cells (Figures 4B
and 4G).
Figure 4. RIP3-Induced ROS Is Required for Efficient Smac Mimetic-Mediated IL-1b
(A) RIP1 kinase activity or lysosomal function do not contribute to Cp. A-induced IL-1b activation. BMDMswere primed with LPS and in the last 20 min of priming,
cells were treated with NH4Cl (20 mM), Bafilomycin A1 (150 nM), or Necrostatin-1 (50 mM) and then incubated with Cp. A for a further 6 hr. IL-1b release was
measured by ELISA. The mean (bars) and measurements of three replicate experiments is shown.
(B) BMDMs of the indicated genotype were primed with LPS. In the last 20min of priming, cells were treated with Glyburide (200 mM), CA-074-Me (20 mM), or E64d
(20 mM) and then incubated with Cp. A (200 nM) for a further 6 hr. Cell supernatants and lysates were analyzed by immunoblot.
(C) BMDMs were primed with LPS and in the last 20 min of priming were incubated with ROS scavenging compounds: Ebselen (210 mM), CAPE (Caffeic acid
phenethyl ester, 210 mM), APDC ((2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate, 100 mM), or NAC (N-Acetyl-L-Cysteine, 20 mM). Cells were then stimulated for
a further 6 hr with alum (200 mg/ml) or Cp. A (200 nM) and cell supernatants and lysates were analyzed by immunoblot.
(D) BMDMs were primed with LPS (3 hr) then treated with NAC for 15 min prior to Cp. A (300 nM) addition for a further 6 hr. IL-1 release was measured by ELISA.
The error bars show the SD of measurements obtained from three mice of each genotype.
(E and F) WT and Ripk3/ BMDMs were treated with 5 mM of CellROX deep red prior to LPS priming (2.5 hr) and Cp. A (300 nM) stimulation for 5 hr. Alternatively
cells were treated with LPS (7.5 hr) and Cp. A (5 hr) alone. The fold change in mean fluorescence intensity (MFI) for LPS-primed and Cp. A-treated cells over cells
treated with LPS alone (E) or for LPS or Cp. A treatment alone over nonstimulated cells (F) is depicted. Propidium iodide-positive cells (less then 20% of cells for
both genotypes and all treatments) were excluded from the analysis. The data was collected from cells derived from three mice of each genotype (symbols) with
the mean and SD (E) presented.
(G) WT and Tnfrsf1a/ BMDMs were primed with LPS and then treated ±glyburide (200 mM) for a further 30min as indicated. Cells were then stimulated with Cp.
A (200 nM) or alum (250 mg/ml) for 6 hr and cell supernatants and lysateswere analyzed by immunoblot. The results obtained in (A) were verified on two (NH4Cl and
Bafilomycin A1) or four (Necrostatin-1) occasions.
The data obtained in (C), (E), (F), and (G) were verified on two to three separate occasions. See also Figure S4.
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Collectively, these data argue that in LPS-primed cells, IAP
inhibition causes RIP3-dependent ROS production and this
promotes IL-1b maturation and secretion by NLRP3-caspase-1
inflammasome-dependent and -independent mechanisms.
These pathways do not involve autocrine TNF production or
lysosomal destabilization, both of which have previously been
implicated in IAP or NLRP3 signaling in other circumstances.
Caspase Activity Is Required for Smac Mimetic-Induced
NLRP3-Caspase-1-Independent IL-1b Maturation
To determine whether caspase inhibition could prevent cas-
pase-1-independent Smac mimetic-induced IL-1b maturation,
we treated cells with the pan-caspase inhibitors Z-VAD-fmk
and Q-VD-Oph. BMDMs treated with Z-VAD-fmk prior to
compound A incubation blocked both NLRP3-caspase-1-
dependent and -independent IL-1b activation (Figure 5A). In
contrast, Q-VD-Ophwas less effective at inhibiting IL-1bmatura-
tion in response to well-characterized NLRP3 agonists (Fig-
ure 5B) and, surprisingly, markedly enhanced compound
A-mediated IL-1b secretion (Figures 5C and S4I).
Caspase-8 inhibits RIP3 signaling, that if left unchecked
causes embryonic lethality (Kaiser et al., 2011; Oberst et al.,
2011). We reasoned that because Q-VD-Oph does not com-
pletely block caspase-1 activity (Figure 5B), but does effectively
inhibit caspase-8, it may allow increased RIP3 signaling upon
compound A stimulation, leading to enhanced NLRP3-cas-
pase-1 cleavage of IL-1b. Consistent with this hypothesis,
when we prevented compound A-induced NLRP3-caspase-1
activation by using Nlrp3/, Pycard/, or Casp1/ BMDCs,
the effect of Q-VD-Oph was reversed, and it reduced compound
A-induced IL-1b activation in these cells (Figures 5C and S4I).
If another caspase can process IL-1b independently of
caspase-1, other caspase-activating signals should be able to
promote IL-1b maturation in a caspase-1-independent manner.
Figure 5. Pan-caspase Inhibition Prevents Caspase-1-Independent IL-1b Activation Caused by Smac Mimetic Treatment
(A) BMDMs of the indicated genotype were primed with LPS. In the last 20 min of priming, cells were incubated with 50 mM of Z-VAD-fmk. Cells were then
stimulated for a further 6 hr with Cp. A (200 nM) or alum (200 mg/ml) and cell supernatants and lysates were analyzed by immunoblot.
(B) BMDMs were primed with LPS. In the last 20 min of priming, cells were incubated with 20 mM of the pan-caspase inhibitors Q-VD-Oph (QVD), Z-VAD-fmk
(ZVAD), or the caspase-1 inhibitor Y-VAD-fmk (YVAD) before treatment with the indicated NLRP3 agonists for a further 6 hr. Cell supernatants were analyzed by
immunoblot.
(C) BMDCs of the indicated genotype were primed with LPS. In the last 20 min of priming, cells were incubated with 10 mM of Q-VD-Oph and then stimulated for
a further 6 hr with Cp. A (200 nM). Cell supernatants and lysates were analyzed by immunoblot.
(D) BMDMs were stimulated with Cp. A (300 nM) as indicated and cell lysates analyzed by immunoblot.
(E and F) WT and Nlrp3/ BMDMs were treated as indicated with Cp. A for 6 hr ± LPS priming. Cell lysates were analyzed by immunoblot (E) and IL-1b secretion
into the supernatant was measured by ELISA (F). The mean (bars) and measurements of two mice of each genotype are shown (F).
(G and H) LPS-primed BMDCs from WT or Ripk3/ mice were treated as indicated with Cp. A or cycloheximide (CHX, 20 mg/ml) (G). Alternatively, LPS-primed
BMDMs fromWT or Tnf/mice were treated ±Necrostatin-1 (50 mM) for 20 min before incubation with Cp. A (200 nM) for a further 6 hr (H). Cell supernatants and
lysates for (G) and (H) were analyzed by immunoblot.
The data presented in (A) and (C) was repeated on two separate occasions and the data presented in (G) and (H) verified on two to four separate occasions. See
also Figures S4 and S5.
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Treatment of LPS-primed BMDMswith staurosporine, cyclohex-
imide, or UVB radiation resulted in both caspase-1-dependent
and -independent processing of IL-1b that occurred indepen-
dent of RIP3 and was therefore inhibited by Z-VAD-fmk and Q-
VD-OPh (Figures S5A–S5D). However, as with Smac mimetic
treatment, cycloheximide, staurosporine and UVB irradiation
triggered IL-1b activation and secretion was blocked by antiox-
idants (Figure S5E) and occurred independent of ATP release
and activation of the purinergic P2X7 receptor (Figure S5F).
Caspase-8 Mediates NLRP3-Caspase-1-Independent
IL-1b Maturation
We examined caspase processing in Smac mimetic-treated cells
to determine which caspase other than caspase-1 might be
cleaving IL-1b. We observed substantial caspase-8 processing
and cFLIPL depletion in compound A-treated WT, Nlrp3
/,
Ripk3/, and Tnf/ BMDMs or BMDCs (Figures 5D, 5E, 5G,
and 5H), and this correlated with NLRP3-caspase-1-independent
IL-1b secretion (Figure 5F). Unlike cycloheximide treatment,
compound A did not induce substantial caspase-9 cleavage, cas-
pase-3 processing to the mature p17 subunit, or PARP cleavage
in this time frame (Figure 5G). Notably, compound A-induced
caspase-8 processing and IL-1b secretion was not blocked by
Necrostatin-1 in LPS-primed WT and Tnf/ BMDMs (Figure 5H).
Consistent with our data obtained with primary macrophages,
RAW 264.7 (which lack ASC) (Pelegrin et al., 2008) and C57BL/6
v-myc/v-raf (WTv-myc/v-raf) immortalized (Bauernfeind et al., 2009)
macrophages secreted mature IL-1b in response to LPS priming
and Smac mimetic or cycloheximide treatment, and this
occurred in the absence of caspase-1 processing (Figures 6A,
S6A, and S6B). Because ASC expression in WTv-myc/v-raf cells
is minimal when compared to BMDCs (Figure 6B), this suggests
that inflammasome activation in these cells is inefficient.
Notably, release of mature IL-1b into the supernatant in both
RAW 264.7 and WTv-myc/v-raf macrophages correlated with cas-
pase-8, but not caspase-9, processing (Figures 6A and S6B).
These results led us to hypothesize that caspase-8 is capable
of processing precursor IL-1b. Although it was less efficient
when compared to caspase-1, recombinant caspase-8 cleaved
purified precursor IL-1b into the same mature 17 kDa fragment
(Figure S6C). In contrast, caspase-9 was markedly less efficient
at cleaving IL-1b than caspase-8. Because caspase-8 deletion
is embryonic lethal (Varfolomeev et al., 1998) and is also required
for myelomonocytic progenitor differentiation (Kang et al., 2004),
we next knockeddowncaspase-8 inWTv-myc/v-raf andRAW264.7
macrophages by shRNA targeting. Depletion of caspase-8
consistently decreased LPS- and compound A-mediated IL-1b
maturation for four different caspase-8 shRNAs (Figures 6C,
S6D, and S6E). A fifth caspase-8 shRNA (no. 81) resulted in
poor growing cells that constitutively secreted IL-1b (Figure 6C).
Although these data imply that caspase-8 can activate IL-1b
independently of caspase-1, they do not exclude the possibility
that another caspase activated downstream of caspase-8 is
responsible for caspase-1-independent IL-1b maturation. To
test this, we generated BMDMs and BMDCs from caspase-3-,
caspase-7-, caspase-2-, or caspase-11-deficient mice.
Because caspase-8 can cleave Bid to induce Bax-Bak activa-
tion, we also examined BMDMs derived from Bid/ mice or
lethally irradiated mice that had been reconstituted with
Bax/Bak1/ fetal liver. However, activation of IL-1b in all
these cells was similar to WT cells when they were primed with
LPS and treated with compound A, alum, or ATP (Figures 6D,
6E, and S7A–S7E).
Collectively, these results argue that as a result of Smac
mimetic-mediated IAP inhibition, caspase-8, but not down-
stream effector caspases, can cleave precursor IL-1b into its
mature biologically active 17 kDa fragment, and that this repre-
sents an alternate mechanism for IL-b activation independent
of inflammasome activity.
IAP Depletion Induces Ripoptosome Formation
and Promotes RIP3-Dependent Caspase-8 Modification
and Activity
IAP depletion has recently been shown to induce the sponta-
neous complexing of RIP1 with caspase-8 and FADD (Feoktis-
tova et al., 2011; Tenev et al., 2011). This complex, termed the
ripoptosome, can activate both RIP3 and caspase-8 signaling.
We hypothesized that IAP depletion in macrophages is likely
to induce ripoptosome formation which drives IL-1b activation
because, consistent with ripoptosome activity, compound
A-induced IL-1b maturation and secretion (1) occurs indepen-
dent of TNF or TNFR1, (2) does not involve Bax and Bak, (3) is
maximal when all three IAPs are deleted, (4) requires RIP3
signaling, and (5) depends partially on caspase-8. In agreement
with these observations and ripoptosome assembly, BMDMs
treated with compound A alone was sufficient to cause
increased RIP1 associated with immunoprecipitated caspase-
8, and this association was increased if cells were primed with
LPS before compound A treatment (Figure 7A). Therefore, IAPs
appear to suppress ripoptosome formation that when activated
can drive the generation of bioactive IL-1b.
Because Ripk3/ BMDCs secrete less IL-1b upon TLR
priming and compound A stimulation when compared in parallel
with Nlrp3/, Pycard/, or Casp1/ cells (Figures 3A and 3E),
this suggests that RIP3 deficiency must also impair caspase-8-
dependent IL-1b maturation. Although compound A-induced
caspase-8 processing is not substantially decreased in LPS-
primed Ripk3/ cells (Figures 5G and 7B), cleaved caspase-8
modification, presumably ubiquitylation, was markedly reduced
when RIP3 was deleted (Figure 7B).
Caspase-8 ubiquitylation is required for caspase-8 seques-
tering into lipid raft membranes and full caspase-8 activity (Jin
et al., 2009). Consistent with this, we observed that in response
to LPS and compound A treatment, cleaved and modified cas-
pase-8 fractionates preferentially into detergent-resistant
membranes (Figure 7B). Importantly, decreased caspase-8
modification in Ripk3/ BMDMs correlated with decreased
compound A-induced caspase-8 activity when compared to WT
BMDMs (Figure 7C). Compound A-induced caspase-8 activity
was also efficiently inhibited by the antioxidant NAC (data not
shown), implicating RIP3-generated ROS in both NLRP3-cas-
pase-1- and caspase-8-mediated IL-1bmaturation (Figure 4D).
DISCUSSION
In this study, we demonstrate that IAP proteins inhibit
ripoptosome formation and RIP3 signaling to prevent NLRP3-
caspase-1- and caspase-8-dependent activation of IL-1.
Immunity
IAP Proteins Limit IL-1 Activity
222 Immunity 36, 215–227, February 24, 2012 ª2012 Elsevier Inc.
RIP3-mediated IL-1 secretion precedes cell death, and this
suggests that RIP3 may influence inflammatory responses inde-
pendent of its ability to induce necroptosis (Wallach et al., 2011).
The identification of these pathways leading to IL-1 activation,
and their suppression by IAPs, may have important implications
for RIP1-RIP3-dependent signaling that has been associated
with the control of viral infection or pathologies such as pancre-
atitis (Vandenabeele et al., 2010).
IAP depletion triggers NLRP3-caspase-1 inflammasome-
dependent IL-1 activation and also enhances IL-1 secretion
induced by other NLRP3 agonists. Removal of the three IAP
proteins XIAP, cIAP1, and cIAP2 is required for maximal
NLRP3-caspase-1 and IL-1b activation. Therefore it is likely that
under normal conditions, or in response to immune cell recogni-
tion of specific PAMPs or DAMPs, these three IAP proteins act in
concert to suppress inappropriate or excess IL-1 activity.
Althoughcaspase-1activation is regardedas theprimarymech-
anism for producing bioactive IL-1b, FasL can induce IL-1bmatu-
ration and secretion that is independent of caspase-1 but is
blocked by pan-caspase inhibition (Miwa et al., 1998). Our data
demonstrate that IAP depletion, and a number of other caspase-
activatingagents, canalso induce IL-1bmaturation in the absence
of caspase-1 activity, and that this is most probably mediated
through IL-1b precursor cleavage by caspase-8. By extension,
Figure 6. IAP Inhibition Causes Caspase-8 Cleavage of Precursor IL-1b that Is Independent of NLRP3-Caspase-1
(A) WTv-myc/v-raf macrophages were primed with LPS and treated with the indicated doses of Cp. A for 6 hr. Cell supernatants and lysates were analyzed by
immunoblot.
(B) ASC levels in BMDCs were compared to WTv-myc/v-raf macrophages by immunoblot. Actin and Panceau staining indicate protein loading.
(C) WTv-myc/v-raf macrophages expressing five different shRNAs targeting caspase-8, or scrambled and TNF control shRNAs, were primed with LPS followed by
Cp. A (300 nM) treatment for 6 hr. Cell supernatants and lysates were analyzed by immunoblot.
(D and E) Bid/ (D) or Bax/Bak1/ (E) BMDMs were primed with LPS ± glyburide (200 mM) treatment in the last 20 min of priming. Cells were subsequently
stimulated with Cp. A or alum (250 mg/ml) for 6 hr or ATP (5 mM) for 1 hr. IL-1b secretion into the supernatant wasmeasured by ELISA. Error bars represent the SD
of nine replicates from three mice of each genotype.
Data in (A)–(C) were verified on three separate occasions and data in (E) on two separate occasions. See also Figures S6 and S7.
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these data suggest that Fas activation of caspase-8 would also
promote IL-1b activity. Caspases activated downstream of cas-
pase-8 are unlikely to contribute to IL-1b activation because cas-
pase-2-, caspase-3-, caspase-7-, and caspase-11-deficient cells
show normal IL-1b activation in response to IAP inhibition. This is
consistent with inefficient IL-1b precursor cleavage by recombi-
nant caspase-3, caspase-7, and caspase-9 and a previous study
suggesting that caspase-8 is required for TLR3- or TLR4-induced
IL-1b secretion (Lu¨thi et al., 2009; Maelfait et al., 2008).
IAP depletion in macrophages induces ripoptosome forma-
tion, which can promote RIP3 and caspase-8 signaling and is
therefore likely to drive subsequent IL-1b activation. Because
RIP1 kinase activity promotes ripoptosome assembly and is
usually required for RIP3 signaling, it was therefore surprising
that the RIP1 kinase inhibitor Necrostatin-1 failed to prevent
Smac mimetic-mediated IL-1b maturation. It is possible that
LPS priming (which contributes to ripoptosome activation)
induces RIP1 kinase activity, and that this pool of ‘‘preactivated’’
RIP1 is not inhibited by subsequent Necrostatin-1 and Smac
mimetic treatment. Alternatively, upon IAP depletion, RIP3 may
be activated independent of RIP1, as suggested for viral-
induced RIP3 signaling (Upton et al., 2010). The unexpected
role for RIP3 in promoting caspase-8 modification and activity
also implies that RIP3 facilitates a negative feedback loop,
because active caspase-8 can process and possibly inactivate
RIP1, RIP3, or CYLD (Feng et al., 2007; Lin et al., 1999; O’Donnell
Figure 7. IAP Depletion Induces Ripoptosome Formation and Promotes RIP3-Dependent Caspase-8 Modification and Activity
(A) BMDMs were primed with LPS (2 hr) and then treated with Q-VD-Oph (10 mM) and Cp. A as indicated. Caspase-8 was immunoprecipitated from cell lysates
and RIP1 association analyzed by immunoblot. Asterisk indicates antibody IgG heavy chain cross reactivity.
(B) WT andRipk3/BMDMswere primedwith LPS and then treatedwith Cp. A (4 hr) as indicated. Cells were lysed directly in reducing sample buffer (total lysate)
or fractionated into Triton X-100 insoluble and soluble fractions and analyzed by immunoblot.
(C) WT and Ripk3/ BMDMs were primed with LPS for 2 hr and then treated for a further 4 hr with Cp. A as indicated. Cellular caspase-8 activity was
thenmeasured (Promega, Caspase-8 Glo assay kit). Measurements were performed in duplicate for three mice of each genotype (symbols). Error bars represent
the SD.
The data in (A) were verified on two separate occasions and the data in (B) and (C) verified on three separate occasions.
Immunity
IAP Proteins Limit IL-1 Activity
224 Immunity 36, 215–227, February 24, 2012 ª2012 Elsevier Inc.
et al., 2011), which is likely to dampen ripoptosome function.
How RIP3 promotes caspase-8 modification remains undeter-
mined, but in this context it is noteworthy that overexpressed
RIP3 can induce caspase activation and apoptotic cell death
(Sun et al., 1999; Yu et al., 1999).
RIP3 is required for necroptotic cell death, which is distinct
from other forms of necrosis that occur independent of RIP3.
Necrotic cells release ATP that can bind to the purinergic P2X7
receptor of healthy cells and can cause NLRP3-caspase-1 in-
flammasome activation (Ghiringhelli et al., 2009; Iyer et al.,
2009; McDonald et al., 2010). In some situations, necrosis induc-
tion or lysosomal destabilization may also activate NLRP3-cas-
pase-1 through an ill-defined pathway that is blocked by the
cathepsin B inhibitor CA-074-Me (Halle et al., 2008; Hornung
et al., 2008; Li et al., 2009). However, we found no evidence
implicating lysosomal function or cathepsin activity in Smac
mimetic-induced IL-1 activation. Our data also show that
Smac mimetic-induced IL-1 activation occurs prior to any
disruption of plasma membrane integrity and is not affected by
the deletion of P2X7. Therefore, we conclude that RIP3 signaling,
but not cell death, is sufficient for IL-1bmaturation and secretion.
EXPERIMENTAL PROCEDURES
Macrophage and Dendritic Cell Preparation, Stimulation,
and IL-1 Analysis
Bone marrow myeloid progenitor cells were differentiated into BMDMs for
7 days in DME (Invitrogen) (37C, 5% CO2) supplemented with 10% FBS and
20% L929 conditioned medium or BMDCs for 8 days in DME supplemented
with 10% FBS and 20 ng/ml of GM-CSF (Immunotools). After differentiation,
adherent (BMDMs) or nonadherent (BMDCs) cells were replated at 2 3
105 cells/well (96-well plates) or 5–63 105 cells/well (24-well plates) andprimed
with 20 ng/ml of ultrapure LPS for 3 hr. Cells were stimulated as indicated and
cell supernatant collected for ELISA (IL-1a, IL-1b, or TNF; R&D systems) and
immunoblot analysis. Cells lysates and supernatants were separated on 8%,
12%, or gradient 4%–12% polyacrylamide gels (Invitrogen) and protein trans-
ferred to nitrocellulose (Amersham) membranes. Membranes were blocked
with 5% skim milk in PBST (PBS containing 0.05% Tween 20) and all primary
antibody incubations were performed overnight and secondary antibody incu-
bations were performed for 1–2 hr. Membranes were washed 5–8 times in
PBST after all antibody incubations. Antibody dilutions were performed with
5%skimmilk in PBST.Micewere treated in accordancewith the Swiss Federal
Veterinary Office guidelines (Switzerland) and under conditions approved by
the Walter and Eliza Hall Institute Animal Ethics Committee (Australia).
Reactive Oxygen Species Measurement
Bone marrow-derived macrophages were seeded at 5 3 105 cells/well
(24-well) tissue culture plates. Cells were labeled with 5 mM of CellROX
Deep Red (Invitrogen) for 30 min (37C, 5% CO2), washed twice, and then
stimulated as indicated in the figure legends. Cells were then harvested and
analyzed by flow cytometry. Viable cells (PI negative) were quantified for
ROS production by calculating the mean fluorescence intensity (MFI) of
5,000 events with Weasel V2.0 analysis software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at doi:10.1016/j.
immuni.2012.01.012.
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